Encyclopedia entry

GHRP-2 (Growth Hormone Releasing Peptide-2)

Evidence: Mixed evidence

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-05-26

Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.

AI-friendly summary · GHRP-2

GHRP-2 is a synthetic hexapeptide ghrelin receptor agonist, developed in the late 1980s and characterised in human pharmacokinetic studies in the 1990s. It produces pulsatile release of endogenous growth hormone from the pituitary. Development as a licensed pharmaceutical was discontinued and it holds no marketing authorisation in any major jurisdiction. No phase II or phase III randomised trials of efficacy for body composition, athletic performance, or anti-ageing have been published. PeptideClear is gathering UK retailer data for GHRP-2; commercial coverage is not yet live.

Mechanism of action

How GHRP-2 works

GHRP-2 binds the growth hormone secretagogue receptor type 1a (GHSR-1a, the ghrelin receptor) on the anterior pituitary and at the hypothalamic arcuate nucleus. Receptor activation triggers pulsatile release of stored endogenous growth hormone from somatotroph cells. The peptide also has modest stimulatory effects on appetite via the ghrelin pathway. Older human pharmacokinetic work documented a short plasma half-life on the order of 15 to 60 minutes, consistent with the pulsatile release profile.

Source: PubMed search: GHRP-2 pharmacokinetics (1990s human characterisation literature)

What the literature shows

The GHRP-2 literature splits into two strands. The first is the older pharmacokinetic characterisation in healthy adult volunteers and in growth-hormone-deficient children, mostly from the 1990s and early 2000s, which established the compound's ghrelin receptor binding profile and its GH-releasing activity. The second strand is broader ghrelin receptor and growth-hormone secretagogue class research, where GHRP-2 is used as a tool compound to interrogate the pathway. Efficacy trials for any specific therapeutic indication did not progress to phase II or III in any major jurisdiction.

· Human pharmacokinetic studies in healthy adult volunteers establishing absorption, half-life, and dose-response GH release profiles (1990s onwards).
· GH stimulation testing in paediatric growth-hormone-deficient populations as a diagnostic challenge.
· Mechanistic pharmacology characterising binding affinity and selectivity at the ghrelin (GHSR-1a) receptor.
· Animal model work on appetite stimulation, body composition, and growth hormone axis biology.
· No published phase II or phase III randomised controlled trials of efficacy for body composition, athletic performance, or anti-ageing indications in healthy adults.
· Listed on the WADA prohibited list for tested athletes, alongside other growth hormone secretagogues.

Related compounds: Ipamorelin (see Ipamorelin encyclopedia entry) is the newer GHRP-family compound with a similar mechanism. CJC-1295 and Sermorelin act at the separate GHRH receptor and are often discussed alongside GHRPs in the growth-hormone-secretagogue category.

UK regulatory status

GHRP-2 sits outside the Misuse of Drugs Act 1971 and outside the Psychoactive Substances Act 2016. It has zero UK marketing authorisations as a medicine. UK retailers can sell it lawfully only by labelling it for "research use only, not for human or animal consumption" and by avoiding any therapeutic claim. It is also on the WADA prohibited list, which is relevant to any tested athlete.

· Not a controlled drug under the Misuse of Drugs Act 1971.
· Not scheduled under the Psychoactive Substances Act 2016.
· No UK marketing authorisation as a medicine.
· No EMA or FDA marketing authorisation in the EU or US.
· Sold legally as a research chemical when marketed without health claims.
· Listed on the WADA prohibited list. Use by a UKAD-tested athlete results in a sanctionable doping finding.
· Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Risks and unknowns

What the literature does not yet show about GHRP-2

Known concerns

Older human pharmacokinetic studies do not constitute efficacy or long-term safety evidence for any consumer indication.
Reported transient elevations in cortisol and prolactin relative to newer, more selective GHRPs such as Ipamorelin.
Appetite stimulation via the ghrelin pathway is a documented secondary effect, with unclear long-term metabolic implications.
WADA prohibited status. Athletes subject to UKAD or international federation testing risk a doping sanction.
Purity of UK research-peptide supply varies. CoA gating and HPLC analysis differ between retailers.

Open questions in the literature

Long-term effects of repeated GH axis stimulation in healthy adults are not characterised in modern ICH-GCP trials.
Whether the modest GH release translates into any measurable change in lean mass, fat mass, or athletic performance in healthy adults has not been formally established.
Optimal route of administration, dosing frequency, and bioavailability profile in humans for any specific consumer indication have not been formally studied.
Interactions with other components of the GH/IGF-1 axis (CJC-1295, Sermorelin, exogenous growth hormone) are not characterised in controlled human trials.

Regulatory note

Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Listed on the WADA prohibited list. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.

Where to learn more

· PubMed search: GHRP-2 returns roughly 200 papers covering pharmacokinetics and ghrelin receptor pharmacology.
· PubMed: GHRP-2 pharmacokinetics for the 1990s human characterisation literature.
· PubMed: ghrelin receptor agonist for broader GHSR-1a pathway context.
· Related compounds: Ipamorelin, CJC-1295, Sermorelin.
· UK retailer purity comparison: research peptides UK retailers.
· WADA prohibited list: wada-ama.org prohibited list.

Frequently asked questions

Is GHRP-2 legal in the UK?

GHRP-2 is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is sold legally by UK research peptide retailers under "research use only, not for human or animal consumption" framing. It holds no UK marketing authorisation as a medicine. GHRP-2 is on the WADA prohibited list for tested athletes.

What does the human evidence show for GHRP-2?

Older human pharmacokinetic studies, primarily from the 1990s and early 2000s, characterised GHRP-2 as a ghrelin receptor agonist that produced measurable, pulsatile growth-hormone release in healthy volunteers and in growth-hormone-deficient populations. No phase II or phase III randomised controlled trials have been published evaluating GHRP-2 for body composition, athletic performance, or anti-ageing indications in humans.

What is the regulatory status of GHRP-2 in the UK?

GHRP-2 has no UK marketing authorisation as a medicine. Development as a licensed pharmaceutical was discontinued and no commercial human product exists in any major regulatory jurisdiction. It is sold as a research chemical when marketed without health claims, and becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims.

How does GHRP-2 differ from Ipamorelin and CJC-1295?

GHRP-2 and Ipamorelin both act at the ghrelin (GHSR-1a) receptor and are categorised as GHRPs. GHRP-2 is the older compound; Ipamorelin was developed later and is generally described as producing less cortisol and prolactin elevation. CJC-1295 is structurally distinct and acts at the GHRH receptor rather than the ghrelin receptor.

Where can I learn more about GHRP-2?

A PubMed search for "GHRP-2" returns roughly 200 papers covering the pharmacokinetic characterisation, ghrelin receptor pharmacology, and growth-hormone secretagogue class research from the 1990s onwards. The "Where to learn more" section above links to the primary sources.

UK retailer coverage

PeptideClear is gathering UK retailer data for GHRP-2. Commercial price comparison and retailer table not yet live for this compound. In the meantime, the UK research peptide retailer directory covers the broader supply landscape.

UK research peptide retailers

Clinical evidence record

Read the clinical evidence record for GHRP-2

Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.

Popular on PeptideClear

Research peptides

BPC-157 (UK)

Collagen

Best UK collagen brands 2026

GLP-1

UK GLP-1 clinics compared

Methodology

CoA Trust Index

Shop

BPC-157 UK prices

Ready to buy

Buy GHRP-2 in the UK

UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.

Buy GHRP-2 in the UK CoA Trust Index